Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetic Considerations in the Elderly

An Update

  • Review Article
  • Special Populations
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

There are a number of areas in which advances have been made over the last few years in the area of pharmacokinetics in the elderly. There is increasing understanding of the diversity of cytochrome P450s (CYP) and the variability of the age-related decline in CYP activity. This has helped to explain some of the interindividual variability in drug metabolism with age. The importance of ethnic differences has emerged, but specific work is needed in this area in the elderly. Differences in the handling of chiral compounds has been reported but as yet no clinically important findings that may lead to a change in clinical practice have emerged. The emerging importance of extrahepatic drug metabolism, especially in the intestine, has added a new complexity to our understanding of pharmacokinetics.

The issue of frailty is also discussed in this article. Whether it will be of value at the bedside has yet to emerge. Nonetheless, as a concept, recent data has supported its potential use to define those more at risk of clinically meaningful pharmacokinetic alterations. Other advances have included the appreciation that selectivity in induction and inhibition in the elderly are due to the existence of multiple CYP forms. Similarly, the role of these various enzymes in disease is also improving our clinical understanding, as exemplified in Parkinson’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dawling S, Crome P. Clinical pharmacokinetics in the elderly: an update. Clin Pharmacokinet 1989; 17: 236–63

    PubMed  CAS  Google Scholar 

  2. Brian WR, Sari M-A, Iwasaki M, et al. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in saccharomyces cerevisiae. Biochemistry 1990; 29: 11280–92

    PubMed  CAS  Google Scholar 

  3. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450 IIIA4. J Med Chem 1991; 34: 1838–44

    PubMed  CAS  Google Scholar 

  4. Wrighton SA. The human hepatic cytochromes P450 involved in human metabolism. Crit Toxicol 1992; 22: 1–21

    CAS  Google Scholar 

  5. Mahgoub A, Idle R, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–6

    PubMed  CAS  Google Scholar 

  6. Watkins PW, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci 1985; 82: 6310–4

    PubMed  CAS  Google Scholar 

  7. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharm Exp Ther 1991; 256: 1189–94

    CAS  Google Scholar 

  8. Vestal RE, Norris AH, Tobin JD, et al. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 425–32

    PubMed  CAS  Google Scholar 

  9. Wood AJJ, Vestal RE, Branch RA, et al. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 1979; 26: 8–15

    PubMed  Google Scholar 

  10. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and ageing. Clin Pharmacokinet 1990; 19: 359–89

    PubMed  CAS  Google Scholar 

  11. Woodhouse K. Drugs and the liver. Part III: ageing of the liver and the metabolism of drugs. Biopharm Drug Dispos 1992; 13: 311–20

    PubMed  CAS  Google Scholar 

  12. Schmucker DL, Woodhouse KW, Wang RK, et al. Effect of age and gender on in vivo properties of human liver microsonal mono-oxygenases. Clin Pharmacol Ther 1990; 48: 365–74

    PubMed  CAS  Google Scholar 

  13. Woodhouse K, James OFW. Hepatic drug metabolism and ageing. Br Med Bull 1990; 46: 22–35

    PubMed  CAS  Google Scholar 

  14. Yelland C, Summerbell J, Nicholson E, et al. The association of age with aspirin esterase activity in human liver. Age Ageing 1991; 20: 16–8

    PubMed  CAS  Google Scholar 

  15. Wynne HA, Kamali F, Edwards C, et al. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing 1996; 25: 429–31

    PubMed  CAS  Google Scholar 

  16. Ayesh R, Idle JR, Richie JC, et al. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984,312: 169–70

    PubMed  CAS  Google Scholar 

  17. Baer AN, McAllister CB, Wilkinson GR, et al. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 843–850

    PubMed  CAS  Google Scholar 

  18. Kaisary A, Smith P, Jaczq E, et al. Genetic predisposition to bladder cancer, ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47: 5488–93

    PubMed  CAS  Google Scholar 

  19. Persad RA, Fleming CM, Wilkinson GR, et al. Bladder cancer recurrance and its association with cytochrome P450IID6 activity. Prog Clin Biol Res 1992; 378: 19–27

    PubMed  CAS  Google Scholar 

  20. Fleming C, Persad R, Kaisery A, et al. Low activity of N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. Pharmacogenetics 1994; 4: 199–207

    PubMed  CAS  Google Scholar 

  21. Johanssen I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825–9

    Google Scholar 

  22. Bourdi M, Gautier JC, Mircheva J, et al. Anti-liver microsomes antibodies and dihydralazine-induced hepatitis: specificity of auto-antibodies and inductive capacity of the drug. Mol Pharmacol 1992; 42: 280–5

    PubMed  CAS  Google Scholar 

  23. Armstrong M, Daly AK, Cholerton S, et al. Mutant debrisoquine hydroxylation genes in Parkinson’s disease. Lancet 1992; 339: 1017–8

    PubMed  CAS  Google Scholar 

  24. Smith AD, Grough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 1992; 339: 1375–7

    PubMed  CAS  Google Scholar 

  25. Stevenson G, Williams AC, Waring RH, et al. Xenobiotic metabolism in motor neurone disease. Lancet 1988; I: 644–7

    Google Scholar 

  26. Bhamre S, Anandatheerathavarada HK, Shankar SK, et al. Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalytic activity. Arch Biochem Biophys 1993; 301: 251–5

    PubMed  CAS  Google Scholar 

  27. Boucher BA, Kuhl DA, Fabian TC, et al. Effect of neurotrauma on hepatic drug clearance. Clin Pharmacol Ther 1991; 50: 487–97

    PubMed  CAS  Google Scholar 

  28. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986; 22: 610–2

    PubMed  CAS  Google Scholar 

  29. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987: II: 939–41

    Google Scholar 

  30. O’Mahony SM, George G, Westlake H, et al. Plasma aspirin esterase activity in elderly patients undergoing elective hip replacement and with fractured neck of femur. Age Ageing 1995; 23: 338–41

    Google Scholar 

  31. Kinirons MT, Lyons D. Pitfalls in prescribing for the elderly. Br J Hosp Med. In press

  32. Hunt CM, Westerkam WR, Stave G, et al. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992; 64: 189–99

    PubMed  CAS  Google Scholar 

  33. Hunt CM, Westerkam WR, Stave GM. Effects of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275–83

    PubMed  CAS  Google Scholar 

  34. Knodell RG, Dubey RK, Wilkinson GR, et al. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 1988; 245: 845–9

    PubMed  CAS  Google Scholar 

  35. Miglioli PA, Pivetta P, Strazzabosco M, et al. Effect of age on single and multiple dose pharmacokinetics of erythromycin. Eur J Clin Pharmacol 1990; 39: 161–4

    PubMed  CAS  Google Scholar 

  36. Robertson DRC, Waller DG, Renwick AG, et al. Age related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297–305

    PubMed  CAS  Google Scholar 

  37. Loi CM, Parker BM, Cusack BJ, et al. Aging and drug interactions: III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther 1997; 80: 627–37

    Google Scholar 

  38. Chandler MH, Scott SR, Blouin RA. Age associated steroselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 1988; 43: 436–41

    PubMed  CAS  Google Scholar 

  39. Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975; 55: 347–59

    PubMed  CAS  Google Scholar 

  40. May DG, Porter J, Wilkinson GR, et al. Frequency distribution of dapsone N-hydroxylase: a putative probe for P4503A4 activity in a Caucasian population. Clin Pharmacol Ther 1994; 55: 492–500

    PubMed  CAS  Google Scholar 

  41. O’Shea D, Davis S, Kim RB, et al. Effect of fasting and obesity in humans on the 6-hydroxylation of chloroxazone: a putative probe for CYP2E1 activity. Clin Pharmacol Ther 1996; 56: 359–67

    Google Scholar 

  42. Kim R, O’Shea D, Wilkinson GR. Relationship in healthy subjects between CYP2E1 genetic polymorphism and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1. Pharmacogenetics 1994; 4: 162–5

    PubMed  CAS  Google Scholar 

  43. Zhou HH, Anthony LB, Roden DM, et al. Quinidine reduces clearance of (+)-propranolol more than ()-propranolol through marked reduction of 4-hydroxylation. Clin Pharmacol Ther 1990; 47: 686–93

    PubMed  CAS  Google Scholar 

  44. Kinirons MT, O’Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 621–9

    PubMed  CAS  Google Scholar 

  45. Heim M, Meyer U. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529–32

    PubMed  CAS  Google Scholar 

  46. Swift CG, Homeida M, Roberts CJC. Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 1978; 14: 149–52

    PubMed  CAS  Google Scholar 

  47. Zhou HH, Koshaji RP, Silberstein DJ, et al. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared to American whites. N Engl J Med 1989; 320: 565–70

    PubMed  CAS  Google Scholar 

  48. Zhou HH, Sheller JR, Nu H, et al. Ethnic differences in response to morphine. Clin Pharmacol Ther 1993; 54: 507–13

    PubMed  CAS  Google Scholar 

  49. Caraco Y, Lagerstrom PO, Wood AJJ. Omeprazole disposition in Caucasians and Chinese subjects [abstract]. Clin Pharmacol Ther 1995; 57: 216A

    Google Scholar 

  50. Kalow W. Interethnic variation in drug metabolism. Trends Pharmacol Sci 1991; 12: 102–5

    PubMed  CAS  Google Scholar 

  51. Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350–73

    PubMed  CAS  Google Scholar 

  52. Schellans JHM, Van Der Wart JHF, Danhof M, et al. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline. in man as assessed by a cocktail approach. Br J Clin Pharmacol 1988; 26: 373–84

    Google Scholar 

  53. Stewart DA, Taylor J, Ghosh S, et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992; 42: 577–80

    PubMed  CAS  Google Scholar 

  54. Hallen B, Bogentoft S, Sandquist S, et al. Tolerability and steady state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinance. Eur J Clin Pharmacol 1989; 36: 487–93

    PubMed  CAS  Google Scholar 

  55. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029–36

    PubMed  CAS  Google Scholar 

  56. Peters WH, Kremers PG. Cytochromes P450 in the intestinal mucosa of man. Biochem Pharmacol 1989; 38: 1535–42

    PubMed  CAS  Google Scholar 

  57. Kolars JC, Swini WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–90

    PubMed  CAS  Google Scholar 

  58. Kolar JC, Schmiedin-Ren P, Schuetz J, et al. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871–8

    Google Scholar 

  59. Kinirons MT, Lang CC, Brown RM, et al. Intestinal cytochrome P4503A: studies in coeliac disease as a human model [abstract]. Therapie 1995; Suppl.: 71A

    Google Scholar 

  60. Schuetz EG, Schuetz JD, McLean Grogan W, et al. Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophysics 1992; 294: 206–14

    CAS  Google Scholar 

  61. Tyndale RF, Sunahara R, Inaba T, et al. Neuronal cytochrome P4502D1 (debrisoquine/sparteine-type). Potent inhibition by () cocaine and nucleoside sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991; 40: 63–8

    PubMed  CAS  Google Scholar 

  62. Kivisto KT, Fritz P, Linder A, et al. Immunohistochemical localisation of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochemistry 1995; 103: 25–9

    PubMed  CAS  Google Scholar 

  63. Williams D, Woodhouse K. The relationship between age and cutaneous aryl hydrocarbon hydrxylase (AHH) activity. Age Ageing 1995; 24: 213–6

    PubMed  CAS  Google Scholar 

  64. Kaminsky LS, Fasco MJ. Small intestine cytochromes P450. Crit Rev Toxicol 1992; 21: 407–22

    CAS  Google Scholar 

  65. Wheller CW, Wrighton SA. Detection of human lung cytochromes P450 that are immunochemically related to cytochrome P4502E1 and cytochrome P4503A4. Biochem Pharmacol 1992; 44: 183–6

    Google Scholar 

  66. Kolars JC, Lown KS, Scmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247–59

    PubMed  CAS  Google Scholar 

  67. Lucey MR, Kolars JC, Merion RM, et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 3A. Lancet 1990; 355: 11–5

    Google Scholar 

  68. Webber IR, Peters WH, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1993; 33: 661–4

    Google Scholar 

  69. Guengerich FP. Inhibition of oral contraceptive steroid-metabolizing enzyme by steroids and drugs. Am J Obstet Gynecol 1991; 63: 2159–63

    Google Scholar 

  70. Gupta SK, Bakran A, Johnson RW, et al. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27: 475–81

    PubMed  CAS  Google Scholar 

  71. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955–6

    PubMed  CAS  Google Scholar 

  72. Nolan L, O’Malley K. Prescribing for the elderly: Part 1. Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–9

    PubMed  CAS  Google Scholar 

  73. Woodhouse KW, Wynne H, Baillie S, et al. Who are the frail elderly? Q J Med 1988; 68: 505–6

    PubMed  CAS  Google Scholar 

  74. William FM, Wynne H, Woodhouse KW, et al. Plasma aspirin esterase: the influence of age and frailty. Age Ageing 1989; 18: 39–42

    Google Scholar 

  75. Wynne H, Cope LH, Herd MD, et al. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19: 419–24

    PubMed  CAS  Google Scholar 

  76. Wynne H, Yelland C, Cope LH, et al. The association of age and frailty in the pharmacokinetics and pharmacodynamics of metaclopramide. Age Ageing 1993; 22: 354–9

    PubMed  CAS  Google Scholar 

  77. Groen H, Horan MA, Roberts NA, et al. The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. Clin Pharmacokinet 1993; 25: 136–44

    PubMed  CAS  Google Scholar 

  78. Isreal BC, Blouin RA, Mclntyre W, et al. Effects of interferon-monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229–35

    Google Scholar 

  79. Zhou HH, Whelan E, Wood AJJ. Lack of effect of age on the stereochemical disposition of propranolol. Br J Clin Pharmacol 1992; 33: 121–3

    PubMed  CAS  Google Scholar 

  80. Chirrey LA, Tan SC, Hutt AJ, et al. Pharmacokinetics of ibuprofen enantiomers in young and elderly volunteers. Age Ageing 1995; 25Suppl. 1: P43

    Google Scholar 

  81. Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin sensitivity. Br J Clin Pharmacol 1995; 40: 203–7

    PubMed  CAS  Google Scholar 

  82. Vestal RE, Wood AJJ, Branch RA, et al. Effects of age and cigarette smoking on propranolol disposition. Clin Ther Pharmacol 1979; 26: 8–15

    CAS  Google Scholar 

  83. Salem SA, Rajjayabun P, Shepard AM, et al. Reduced induction of drug metablism in the elderly. Age Ageing 1978; 7: 68–73

    PubMed  CAS  Google Scholar 

  84. Twum-Barina Y, Finnegan T, Habash AI, et al. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 1984; 17: 595–7

    Google Scholar 

  85. George G, Wynne H, Woodhouse KW. The association of age with induction of drug metabolising enzymes in human monocytes. Age Ageing 1990; 19: 364–7

    PubMed  CAS  Google Scholar 

  86. George G, Wynne H, Woodhouse KW. Age and the rate of induction of aryl hydrocarbon hydroxylase in isolated peripheral blood monocytes. Age Ageing 1991; 20: 421–3

    PubMed  CAS  Google Scholar 

  87. George G, O’Mahony S, Woodhouse K. Age, smoking and activity of mono-oxygenase aryl hydrocarbon hydroxylase in isolated human peripheral blood monocytes. Age Ageing 1994; 23: 421–4

    PubMed  CAS  Google Scholar 

  88. Bammel A, van derMee K, Ohnhaus EE, et al. Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone. Eur J Clin Pharmacol 1992; 42: 641–4

    PubMed  CAS  Google Scholar 

  89. Guengerich FP. Characterisation of human cytochrome P450 enzymes. FASEB J 1992; 6: 745–8

    PubMed  CAS  Google Scholar 

  90. Rost KL, Brosicke H, Heinmeyer G, et al. Specific and dose dependent enzyme induction by omeprazole in human beings. Hepatology 1995; 20: 1204–12

    Google Scholar 

  91. Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam pharmacokinetics. Br J Clin Pharmacol 1987; 23: 759–63

    PubMed  CAS  Google Scholar 

  92. Zhou HH, Anthony L, Wood AJJ, et al. Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990; 30: 471–5

    PubMed  CAS  Google Scholar 

  93. Atiba JO, Blaschke T, Wilkinson GR. Effects of ketoconazole on the polymorphic 4-hydroxylation of S-mephenytoin and debrisoquine. Br J Clin Pharmacol 1989; 28: 161–5

    PubMed  CAS  Google Scholar 

  94. Kinirons MT, Morike K, Shay S, et al. Does selective inhibition of cytochrome P450s occur with aging? [abstract]. Clin Res 1994; 42: 215A

    Google Scholar 

  95. Kinirons MT, Krivoruk Y, Wilkinson GR, et al. Cytochrome P4503A and the dapsone recovery ratio: lack of inhibition by ketoconazole [abstract]. Clin Pharmacol Ther 1995; 57: 186A

    Google Scholar 

  96. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268–9

    PubMed  CAS  Google Scholar 

  97. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997 Aug; 33(2): 103–21

    PubMed  CAS  Google Scholar 

  98. Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399–403

    PubMed  CAS  Google Scholar 

  99. Ahsan CH, Renwick AG, Waller DG, et al. The influence of dose and ethnic origins on pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329–38

    PubMed  CAS  Google Scholar 

  100. Raschid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51–8

    Google Scholar 

  101. Houghton IT, Chan K, Wong YC, et al. Pethidine pharmacokinetics after intramuscular dose: a comparison in Caucasian, Chinese and Nepalese patients. Methods Find Exp Clin Pharmacol 1992; 14: 451–8

    PubMed  CAS  Google Scholar 

  102. Tomatore KM, Biocevich DM, Reed K, et al. Methylprednisolone pharmacokinetics, cortisol response and adverse effects in black and white renal transplant recipients. Transplantation 1995; 59: 729–36

    Google Scholar 

  103. Lam YW, Jann MW, Chang WH, et al. Intra- and inter-ethnic variability in reduced haloperidol to haloperidol ratios. J Clin Pharmacol 1995; 35: 128–36

    PubMed  CAS  Google Scholar 

  104. Chiba K, Ishizaki T, Wilkinson GR. Chlorzoxazone (CZX) 6-hydroxylation in Japanese and Caucasians [abstract]. Clin Pharmacol Ther 1995; 57: 217A

    Google Scholar 

  105. Zhou HH, Adedoyin A, Wood AJJ. Differing effects of atropine on heart rate in Chinese and White subjects. Clin Pharmacol Ther 1992; 52: 120–4

    PubMed  CAS  Google Scholar 

  106. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Age Research Unit, King’s College School of Medicine and Dentistry, London, England

    Mark T. Kinirons

  2. Department of Geriatric Medicine, Keele University, Stoke-on-Trent, England

    Peter Crome

Authors
  1. Mark T. Kinirons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Crome
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kinirons, M.T., Crome, P. Clinical Pharmacokinetic Considerations in the Elderly. Clin. Pharmacokinet. 33, 302–312 (1997). https://doi.org/10.2165/00003088-199733040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199733040-00005

Keywords

Search

Navigation